Passage Bio (PASG)
(Delayed Data from NSDQ)
$1.04 USD
-0.05 (-4.59%)
Updated Jun 12, 2024 03:59 PM ET
After-Market: $1.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PASG 1.04 -0.05(-4.59%)
Will PASG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PASG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PASG
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
PASG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PASG
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
Optimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy Rating
Passage Bio price target lowered by $1 at Canaccord, here's why
PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024